Drug-delivery research shows early promise
Nanotechnology drug delivery could provide breakthrough in cancer treatment
Amiji and his collaborators from the Colleges of Arts and Sciences and Engineering at the University in Boston, Massachusetts, US have been awarded R21 grants by the National Institutes of Health (NIH) to support their research. The NIH’s R21 programme encourages novel and high-risk/high-reward research by providing support for the early and conceptual stages of project development.
The National Cancer Institute has awarded a two-year, US$350,000 grant to develop more potent therapies for killing cancer cells that become resistant after initial chemotherapeutic treatment.
Amiji, working with chemistry and chemical biology professors Robert Hanson and Max Diem, will explore whether including the cell killer ceramide as a part of chemotherapy will kill tumour cells that are resistant to other treatments. Using nanocarrier technology, the combination treatment would be delivered directly to a cancer cell’s mitochondria to trigger cell death.
The National Institute of Neurological Diseases and Stroke has awarded a two-year, US$475,000 grant to Amiji and chemical engineering professor Rebecca Carrier to examine a ‘nano-emulsion’ system of delivery that will allow drugs to cross the blood-brain barrier. The process could greatly increase the recovery chances of a patient with Parkinson’s or HIV/AIDS, because ‘having a system to get these drug therapies to their appropriate place of action is critical,’ said Amiji.
Current drugs developed for treating brain diseases cannot reach the brain 98% of the time because of the low permeability of the blood-brain barrier. Researchers are investigating whether a nano-sized mixture of water, oil droplets rich in omega-3 fatty acids and curcumin, an Indian spice, will help drugs cross the blood-brain barrier by increasing its permeability.
You may also like
Research & Development
Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research
Read moreTwo life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Trending Articles
Upcoming event
You may also like
Research & Development
Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research
Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Drug Delivery
How are biotech companies using microspheres to go beyond oncology?
Biotech companies are increasingly using microsphere drug delivery technology to expand advanced therapies beyond traditional cancer treatments. In oncology, microspheres (e.g. drug-eluting beads) have been used to localise chemotherapy and reduce side effects
Drug Delivery
Nose-to-brain delivery outperforms systemic BBB technologies according to MetP Pharma
The pioneering company has published preclinical data that strongly supports the advantages of its proprietary nose-to-brain drug delivery technology compared with systemic blood-brain barrier transporter approaches. The results also suggest strong support for therapeutically relevant clinical effects of semaglutide using MetP Pharma’s DDT
Research & Development
AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic
The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies